[Dynamics of the changes in insulin requirement during the treatment with biosynthetic human insulin]

Abstract

In 20 patients treated previously with porcine insulin human recombined insulin Eli Lilly was tried. During one year of its use under strict therapeutic conditions a significant decrease of the requirement for insulin was achieved, especially in the first three months of the trial, especially in patients with shorter duration of diabetes. At the same time, carbohydrate metabolism improved significantly. No side effects of the new insulin were noted.